Altered CD8+ T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis

Clinical and Experimental Immunology

Volumn 132, Issue 1, 2003, Pages 137-143

  Höllsberg, Per ^a   Hansen, H J ^b   Haahr, S ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

ELIspot; Herpesvirus; HLA; Lymphocytes; Peptides

Indexed keywords

CD8 ANTIGEN; CELL NUCLEUS ANTIGEN; EPITOPE; HLA A2 ANTIGEN; HLA B7 ANTIGEN;

ADULT; ARTICLE; AUTOIMMUNITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CYTOMEGALOVIRUS; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION;

ADULT; ANTIGENS, VIRAL; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HLA-A2 ANTIGEN; HLA-B7 ANTIGEN; HUMANS; IMMUNODOMINANT EPITOPES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0347997289     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02114.x     Document Type: Article

References (42)

1. Yewdell JT, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Ann Rev Immunol 1999; 17:51-88.
2. Messaoudi I, Patiño JAG, Dyall R, LeMaoult J, Nikolich-Zugich J. Direct link between mhc polymorfism, T cell avidity, and diversity in immune defence. Science 2002; 298:1797-800.
3. Rooney CM, Smith CA, Ng CYC et al. Use of gene-modified virus-specific T-lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345:9-13.
4. Roskrow MA, Suzuki N, Gan YJ et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998; 91:2925-34.
5. Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci 1999; 96:10391-6.
6. Bharadwaj M, Moss DJ. Epstein-Barr virus vaccine: a cytotoxic T-cell-based approach. Expert Rev Vaccines 2002; 1:467-76.
7. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Ann Rev Microbiol 2000; 54:19-48.
8. + T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002; 195:893-905.
9. Davenport MP, Fazou C, McMichael AJ, Callan MFC. Clonal selection, clonal senescence, and clonal succession: the evolution of the T cell response to infection with a persistent virus. J Immunol 2002; 168:3309-17.
10. + T cell responses in EBV infection. J Immunol 2001; 167:4450-7.
11. Annels NE, Callan MFC, Tan L, Rickinson AB. Changing patterns of dominant RCR usage with maturation of an EBV-specific cytotoxic T cell response. J Immunol 2000; 165:4831-41.
12. Steven NM, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB. Immediate early and early lytic cycle proteins are frequenct targets of the Epstein-Barr virus-induced cytotosic T cell response. J Exp Med 1997; 185:1605-17.
13. Bharadwaj M, Burrows SR, Burrows JM, Moss DJ, Catalina M, Khanna R. Longitudinal dynamics of antigen-specific CD8 (+) cytotoxic T lymphocytes following primary Epstein-Barr virus infection. Blood 2001; 98:2588-9.
14. Callan MFC, Tan L, Annels N et al. Direct visualization of antigen-specific CD8 (+) T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med 1998; 187:1395-402.
15. Tan LC, Gudgeon N, Annels NE et al. Are-evaluation of the frequency of CD8 (+) T cells specific for EBV in healthy virus carriers. J Immunol 1999; 162:1827-35.
16. Dyment DA, Sadnovich AD, Ebers GC. Genetics of multiple sclerosis. Hum Mol Genet 1997; 6:1693-8.
17. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995; 47:425-48.
18. Haahr S, Höllsberg P. The ability of candidate viruses to explain epidemiological findings in multiple sclerosis. In: Hommes OR, Wekerle H, Clanet M, eds Genes and viruses in multiple sclerosis. Amsterdam: Elsevier Science BV, 2001:163-84.
19. Ascherio A, Munger KL, Lennette ET et al. Epstein-Barr virus antibodies and risk of multiple sclerosis - a prospective study. JAMA 2001; 286:3083-8.
20. Haahr S, Koch-Henriksen N, Møller-Larsen A, Eriksen LS, Andersen HMK. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Multiple Sclerosis 1995; 1:73-7.
21. Bech E, Lycke J, Gadeberg P et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002; 58:31-6.
22. Burrows SR, Gardner J, Khanna R et al. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol 1993; 75:2489-93.
23. Kerr BM, Kienzle N, Burrows JM et al. Identification of type B-specific and cross-reactive cytotoxic T-lymphocyte responses to Epstein-Barr virus. J Virol 1996; 70:8858-64.
24. Lee SP, Thomas WA, Murray RJ et al. HLA-A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 1993; 67:7428-35.
25. Scotet E, DavidAmeline J, Peyrat MA et al. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med 1996; 184:1791-800.
26. Hill A, Worth A, Elliott S et al. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. Eur J Immunol 1995; 25:18-24.
27. Nanan R, Carstens C, Kreth HW. Demonstration of virus-specific CD8 (+) memory T cells in measles-seropositive individuals by in vitro peptide stimulation. Clin Exp Immunol 1995; 102:40-5.
28. Solache A, Morgan CL, Dodi AI et al. Identification of three HLA-A*0201-restricted cytotosic T cell epltopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol 1999; 163:5512-8.
29. Kern F, Surel IP, Faulhaber N et al. Target structures of the CD8 (+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 1999; 73:8179-84.
30. Fogdell-Hahn A, Ligers A, Gronning M, Hillert J, Olerup O. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000; 55:140-8.
31. Brehm MA, Pinto AK, Daniels KA, Schneck JP, Welsh RM, Selin LK. T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens. Nat Immunol 2002; 3:627-34.
32. Wandinger KP, Jabs W, Siekhaus A et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55:178-84.
33. Fraser KB, Haire M, Millar JHD, McCrea S. Increased tendency to spontaneous in vitro lymphocyte-transformation in clinically active multiple sclerosis. Lancet 1979; 2:715-7.
34. Munch M, Møller-Larsen A, Christensen T, Morling N, Hansen HJ, Haahr S. B-lymphoblastoid cell-lines from multiple sclerosis patients and a healthy control producing a putative new human retrovirus and Epstein-Barr virus. Multiple Sclerosis 1995; 1:78-81.
35. + suppressor T cells: more questions than answers. Nat Rev Immunol 2002; 2:389-400.
36. +CD25 (high) regulatory cells in human peripheral blood. J Immunol 2001; 167:1245-53.
37. Welsh RM, Selin LK. No one is naïve: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2:417-26.
38. Shimojo N, Maloy WL, Anderson RW, Biddison WE, Coligan JE. Specificity of peptide binding by the HLA-A2.1 molecule. J Immunol 1989; 143:2939-47.
39. Wedemeyer H, Mizukoshi E, Davis AR, Bennink JR, Rehermann B. Cross-reactivity between hepatitis C virus and influenza A virus determinant-specific cytotoxic T cells. J Virol 2001; 75:11392-400.
40. Kim SK, Brehm MA, Welsh RM, Selin LK. Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. J Immunol 2002; 169:90-8.
41. Misko IS, Cross SM, Khanna R et al. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Proc Natl Acad Sci USA 1999; 96:2279-84.
42. Wucherpfennig KW, Strominger JL. Molecular mimicry in T-cell-mediated autoimmunity - viral peptides activate human T-cell clones specific for myelin basic protein. Cell 1995; 80:695-705.